OMAHA, Neb., March 14, 2011 /PRNewswire/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) today announced the completion of an expanded license with the Dana-Farber Cancer Institute, Boston, MA, for the COLD-PCR (CO-amplification at Lower Denaturing temperature PCR) technology. Previously, Transgenomic had licensed exclusive rights to COLD-PCR for Sanger Sequencing and mitochondrial DNA analysis. The new license expands the technology covered to include Ice COLD-PCR, a technique that further extends the sensitivity of mutation detection provided by this key technology and also extends the Company's licensed exclusivity to include analysis of COLD-PCR products by Pyrosequencing.
COLD-PCR is a genetic testing approach that selectively amplifies mutant DNA by recognizing that mutant DNA strands denature at lower temperatures in a PCR reaction than normal DNA. Using this proprietary technique, COLD-PCR amplifies mutated DNA with minimal amplification of the normal DNA. The resultant PCR-amplified fragment can be easily analyzed with a variety of sequencing approaches including Sanger sequencing, Pyrosequencing, real-time PCR or any next generation sequencing technology. Transgenomic has licensed rights to utilize any of these techniques. The enhanced analytic sensitivity of COLD-PCR allows clinicians to use smaller amounts of sample for their genetic analysis and less intrusive sample collection methods such as a blood draw for serum or plasma preparation, urine, fine needle aspirates or bronchial lavage as well as studying mutated DNA in tumors directly. The addition of the Ice COLD-PCR methodology further enhances the sensitivity.
Craig Tuttle, Transgenomic CEO, noted: "One of our long-term corporate strategic initiatives has been to continually develop ultra-high sensitivity assays and technologies for the detection of low level DNA mutations. Ice COLD-PCR enable